Medtronic's brain stimulation tech implanted in epilepsy trial subjects:
This article was originally published in Clinica
Intercept, Medtronic's investigational deep brain stimulation (DBS) technology, has been implanted in all 110 patients in a trial of the system currently underway in the US. The SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial is evaluating the technology for the treatment of medically refractory epilepsy, which does not respond to antiepileptic drugs. Results are expected next year. Intercept employs the same technique and equipment used in Activa, Minneapolis, Minnesota-based Medtronic's FDA-approved treatment for Parkinson's. Epilepsy and seizures are thought to affect more than three million Americans of all ages, at an estimated annual cost of $12.5bn in direct and indirect costs, say the Epilepsy Foundation.